Status:
UNKNOWN
Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
Lead Sponsor:
Campus Bio-Medico University
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Brief Summary
Objective: To determine in real life the efficacy, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chronic (CM) migraine. Design: This prospec...
Detailed Description
GARLIT is an independent, multicenter, prospective, cohort, real-life study. All consecutive patients aged 18 or older with a diagnosis of HFEM (8-14 migraine days per month) or CM (1.3 ICHD-3), who h...
Eligibility Criteria
Inclusion
- the clinical indication for Galcanezumab as a preventive treatment for Migraine according to European Medicines Agency
- age18 years or older
- 8 or more mean Monthly Migraine Headache days in the last three months
Exclusion
- \- previous exposure to any monoclonal antibodies inhibiting CGRP pathway, including clinical trials
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04803513
Start Date
November 1 2019
End Date
August 31 2022
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Campus Bio Medico University Hospital
Rome, RM, Italy, 00122